Michel de Rosen
From Wikipedia, the free encyclopedia
Michel de Rosen (born 1951-02-18) is Chief Executive Officer and Chairman of the Board of Directors of ViroPharma Incorporated (since 2002-08-22), President and Chief Executive Officer (since August 2000), and Director (since May 2000.)
From 1982 to 1999, de Rosen held several positions in Rhone-Poulenc (France) and Rhone-Poulenc Rorer (USA) (now Sanofi-Aventis), including Chief Executive Officer from May 1995 until December 1999, and Chairman of the Board of Directors from 1996 to 1999.
From 1976 to 1982 de Rosen was auditor at the French Ministries of Finance and Defense.
de Rosen holds an MBA from the École des Hautes Études Commerciales.
de Rosen is or has been on a number of boards:
- ABB Ltd (director, since 2002);
- Aspen Institute [1] (mentor)
- Global Business Coalition on HIV/AIDS [2] (director)
- HTH Worldwide [3];(advisor)
- InnaPhase Corporation (director, July 2000 - September 2004)
- Pennsylvania Bio [4] (director)
- Ursinus College [5] (trustee)
In an interview with the British newspaper The Sunday Telegraph on 1995-10-08 he was quoted as saying that he ...sees RPR as a mixture of 'hunting' - growing the company by swooping on acquisition 'prey' - and 'farming', less glamorous but vital organic growth and development of new drugs.
